# The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus

> **NCT04217291** · PHASE2 · COMPLETED · sponsor: **Suzhou Yabao Pharmaceutical R&D Co., Ltd.** · enrollment: 200 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** SY-004
- **OTHER:** SY-004 matching placebo

## Key facts

- **NCT ID:** NCT04217291
- **Lead sponsor:** Suzhou Yabao Pharmaceutical R&D Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-10
- **Primary completion:** 2021-07-09
- **Final completion:** 2021-07-09
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2022-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04217291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04217291, "The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04217291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*